Optimal drug cocktail design: Methods for targeting molecular ensembles and insights from theoretical model systems

Journal of Chemical Information and Modeling

Volumn 48, Issue 5, 2008, Pages 1055-1073

  Radhakrishnan, Mala L ^a,b,e   Tidor, Bruce ^a,c,d  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c Massachusetts Institute of Technology Cambridge   (United States)

^d USA   (United States)

^e WELLESLEY COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING ENERGY; DESIGN; DISEASES; ELECTROSTATICS; MOLECULES; TOXICITY;

BINDING AFFINITIES; BINDING INTERFACE; ELECTROSTATIC PROPERTIES; FUNCTIONAL MUTANTS; OPTIMIZATION FRAMEWORK; OPTIMIZATION METHOD; OPTIMIZATION PROBLEMS; THEORETICAL MODELING;

INTEGER PROGRAMMING;

ARTICLE; BIOLOGICAL MODEL; DRUG COMBINATION; DRUG DESIGN; DRUG RESISTANCE; ELECTRICITY; MUTATION;

DRUG COMBINATIONS; DRUG DESIGN; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; ELECTROSTATICS; MODELS, BIOLOGICAL; MUTATION;

EID: 45749135146     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci700452r     Document Type: Article

References (90)

1. Druker, B, J.; Tamura, S.; Buchdunger, E.; Ohno, S.; Segal, G. M.; Fanning, S.; Zimmerman, J.; Lydon, N. B. Effects of a Selective Inhibitor of the Abl Tyrosine Kinase on the Growth of Bcr-Abl Positive Cells. Nat. Med. 1996, 2, 561-566.
2. Ottmann, O. G.; Druker, B. J.; Sawyers, C. L.; Goldman, J. M.; Reiffers, J.; Silver, R. T.; Tura, S.; Fischer, T.; Deininger, M. W.; Schiffer, C. A.; Baccarani, M.; Gratwohl, A.; Hochhaus, A.; Hoelzer, D.; Fernandes-Reese, S.; Gathmann, I.; Capdeville, R.; O'Brien, S. G. A Phase 2 Study of Imatinib in Patients with Relapsed or Refractory Philadephia Chromosome-Positive Acute Lymphoid Leukemias. Blood 2002, 100, 1965-1971.
3. Little, S. J.; Holte, S.; Routy, J. P.; Daar, E. S.; Markowitz, M.; Collier, A. C.; Koup, R. A.; Mellors, J. W.; Connick, E.; Conway, B.; Kilby, M.; Wang, L.; Whitcomb, J. M.; Hellmann, N. S.; Richman, D. D. Antiretroviral-Drug Resistance Among Patients Recently Infected with HIV. New Eng. J. Med. 2002, 347, 385-394.
4. Grant, R. M.; Hecht, F. M.; Warmerdam, M.; Liu, L.; Liegler, T.; Petropoulos, C. J.; Hellman, N. S.; Chesney, M.; Busch, M. P.; Kahn, J. O. Time Trends in Primary HIV-1 Drug Resistance Among Recently Infected Persons. J. Am. Med. Assoc. 2002, 255, 181-188.
5. Deeks, S. G. Treatment of Antiretroviral-Drug-Resistant HIV-1 Infection. Lancet 2003, 362, 2002-2011.
6. Daub, H.; Specht, R.; Ullrich, A. Strategies to Overcome Resistance to Targeted Protein Kinase Inhibitors. Nat. Rev. Drug Discovery 2004, 3, 1001-1010.
7. Yin, P. D.; Das, D.; Mitsuya, H. Overcoming HIV Drug Resistance Through Rational Drug Design Based on Molecular, Biochemical, and Structural Profiles of HIV Resistance. Cell. Mol. Life Sci. 2006, 63, 1706-1724.
8. Koh, Y.; Nakata, H.; Maeda, K.; Ogata, H.; Bilcer, G.; Devasamudram, T.; Kincaid, J. F.; Boross, P.; Wang, Y. F.; Ties, Y. F.; Volrath, P.; Gaddis, L.; Harrison, R. W.; Weber, I. T.; Ghosh, A. K.; Mitsuya, H. Novel Bis-Tetrahydrofuranylurethane-Containing Nonpeptidic Protease Inhibitor (PI) UIC-94017 (TMC-114) with Potent Activity against Multi-PI-Resistant Human Immunodeficiency Virus in vitro. Antimicrob. Agents Chemother. 2003, 47, 3123-3129.
9. King, N. M.; Prabu-Jerabalan, M.; Nalivaika, E. A.; Wigerinck, P.; de Bethune, M.-P.; Schiffer, C. A. Structural and Thermodynamic Basis for the Binding of TMC114, a Next-Generation Human Immunodeficiency Virus Type I Protease Inhibitor. J. Virol. 2004, 78, 12012-12021.
10. Surleraux, D. L. N. G.; Tahri, A.; Verschueren, W. G.; Pille, G. M. E.; de Kock, H. A.; Jonckers, T. H. M.; Peeters, A.; De Meyer, S.; Azijn, H.; Pauwels, R.; de Bethune, M. P.; King, N.; Prabu-Jeyabalan, M.; Schiffer, C. A.; Wigerinck, P. B. T. P. Discovery and Selection of TMC114, a Next Generation HIV-1 Protease Inhibitor. J. Med. Chem. 2005, 48, 1813-1822.
11. Weisberg, E.; Manley, P.; Mestan, J.; Cowan-Jacob, S.; Ray, A.; Griffin, J. D. AMN107 (Nilotinib): a Novel and Selective Inhibitor of BCR-ABL. Br. J. Cancer 2006, 94, 1765-1769.
12. Golemovic, M.; Verstovsek, S.; Giles, F.; Cortes, J.; Manshouri, T.; Manley, P. W.; Mestan, J.; Dugan, M.; Alland, L.; Griffin, J. D.; Arlinghaus, R. B.; Sun, T.; Kantarijan, H.; Beran, M. AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, has in vitro Activity Against Imatinib-Resistant Chronic Myeloid Leukemia. Clin. Cancer Res. 2005, 11, 4941-4947.
13. Weisberg, E.; Manley, P. W.; Breitenstein, W.; Bruggen, J.; Cowan-Jacob, S. W.; Ray, A.; Huntly, B.; Fabbro, D.; Fendrich, G.; Hall-Meyers, E.; Kung, A. L.; Mestan, J.; Daley, G. Q.; Callahan, L.; Catley, L.; Cavazza, C.; Mohammed, A.; Neuberg, D.; Wright, R. D.; Gilliland, D. G.; Griffin, J. D. Characterization of AMN107, a Selective Inhibitor of Native and Mutant Bcr-Abl. Cancer Cell 2005, 7, 129-141.
14. Shah, N. P.; Tran, C.; Lee, F. Y.; Chen, P.; Norris, D.; Sawyers, C. L. Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor. Science 2004, 305, 399-401.
15. O'Hare, T.; Corbin, A. S.; Druker, B. J. Targeted CML Therapy: Controlling Drug Resistance, Seeking Cure. Curr. Opin. Genet. Devel. 2006, 16, 92-99.
16. Burgess, M. R.; Skaggs, B. J.; Shah, N. P.; Lee, F. Y.; Sawyers, C. L. Comparative Analysis of Two Clinically Active BCR-ABL Kinase Inhibitors Reveals the Role of Conformation-Specific Binding in Resistance. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 3395-3400.
17. O'Hare, T. O.; Walters, D. K.; Stroffregen, E. P.; Sherbenou, D. W.; Heinrich, M. C.; Deininger, M. W. N.; Druker, B. J. Combined Abl Inhibitor Therapy for Minimizing Drug Resistance in Chronic Myeloid Leukemia: Src/Abl Inhibitors are Compatible with Imatinib. Clin. Cancer Res. 2005, 11, 6987-6993.
18. Kovalevsky, A. Y.; Tie, Y.; Liu, F.; Boross, P. I.; Wang, Y.-F.; Leshchenko, S.; Ghosh, A. K.; Harrison, R. W.; Weber, I. T. Effectiveness of Nonpeptide Clinical Inhibitor TMC-114 on HIV-1 Protease with Highly Drug Resistant Mutations D30N, I50V, and L90M. J. Med. Chem. 2006, 49, 1379-1387.
19. Shafer, R. W.; Jung, D. R.; Betts, B. J.; Xi, Y.; Gonzales, M. J. Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database. Nucleic Acids Res. 2000, 25, 346-348.
20. Staszewski, S.; Morales-Ramirez, J.; Tashima, K. T.; Rachlis, A.; Skiest, D.; Stanford, J.; Stryker, R.; Johnson, P.; Labriola, D. F.; Farina, d.; Manion, D. J.; Ruiz, N. M. Efavirenz Plus Zidovudine and Lamivudine, Efavirenz Plus Indinavir, and Indinavir Plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in Adults. New Engl. J. Med. 1999, 341, 1865-1873.
21. Bonfanti, P.; Capetti, A.; Rizzardini, G. HIV Disease Treatment in the Era of HAART. Biomed. Pharmacother. 1999, 53, 93-105.
22. Murphy, E. L.; Collier, A. C.; Kalish, L. A.; Assmann, S. F.; Para, M. F.; Flanigan, T. P.; Rumar, P. N.; Mintz, L.; Wallach, F. R.; Nemo, G. J. Highly Active Antiretroviral Therapy Decreases Mortality and Morbidity in Patients with Advanced HIV Disease. Ann. Intern. Med. 2001, 135, 17-26.
23. Watkins, R. E.; Wisely, G. B.; Moore, L. B.; Collins, J. L.; Lambert, M. H.; Williams, S. P.; Wilson, T. M.; Kliewer, S. A.; Redinbo, M. R. The Human Nuclear Xenobiotic Receptor PXR: Structural Determinants of Directed Promiscuity. Science 2001, 292, 2329-2333.
24. Ekroos, M.; Sjogren, T. Structural Basis for Ligand Promiscuity in Cytochrome P450 3A4. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 13682-13687.
25. Olsen, S. K.; Ibrahimi, O. A.; Raucci, A.; Zhang, F. M.; Eliseenkova, A. V.; Yoyan, A.; Basilico, C.; Linhardt, R. J.; Schlessinger, J.; Mohammadi, M. Insights into the Molecular Basis for Fibroblast Growth Factor Receptor Autoinhibition and Ligand-Binding Promiscuity. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 935-940.
26. Ma, B.; Kumar, S.; Tsai, C.-J.; Nussinov, R. Folding Funnels and Binding Mechanisms. Protein Eng. 1999, 12, 713-720.
27. Vaughn, J. L.; Feher, V. A.; Bracken, C.; Cavanagh, J. The DNA-Binding Domain in the Bacillus subtilis Transition-State Regulator AbrB Employs Significant Motion for Promiscuous DNA Recognition. J. Mol. Biol. 2001, 305, 429-439.
28. Sotriffer, C. A.; Kramer, O.; Klebe, G. Probing Flexibility and "Induced-Fit" Phenomena in Aldose Reductase by Comparative Crystal Structure Analysis and Molecular Dynamic Simulations. Proteins: Struct., Funct., Bioinformat. 2004, 56, 52-66.
29. Bailey, R. W.; Dunker, A. K.; Brown, C. J.; Gerner, E. C.; Griswold, M. D. Clusterin, a Binding Protein with a Molten Globule-like Region. Biochemistry 2001, 40, 11828-11840.
30. Bencharit, S.; Morton, C. L.; Hyatt, J. L.; Kuhn, P.; Danks, M. K.; Potter, P. M.; Redinbo, M. R. Crystal Structure of Human Carboxy-lesterase 1 Complexed with the Alzheimer's Drug Tacrine: From Binding Promiscuity to Selective Inhibition. Chem. Biol. 2003, 10, 341-349.
31. Huang, K.; Kapadia, G.; Zhu, P.-P.; Peterkofsky, A.; Herzberg, O. A Promiscuous Binding Surface: Crystal Structure of the IIA Domain of the Glucose-Specific Permease from Mycoplasma Capricolum. Structure 1998, 6, 697-710.
32. Charnock, S. J.; Bolam, D. N.; Szabo, L.; McKie, V. A.; Gilbert, H. J.; Davies, G. J. Promiscuity in Ligand-Binding: The Three-Dimensional Structure of a Piromyces Carbohydrate-Binding Module, CBM29-2, in Complex with Cello- and Mannohexaose. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 14077-14082.
33. Hopkins, A. L.; Mason, J. S.; Overington, J. P. Can We Rationally Design Promiscuous Drugs? Curr. Opin. Struct. Biol. 2006, 16, 127-136.
34. Freire, E. Designing Drugs Against Heterogeneous Targets, Nat. Biotechnol. 2002, 20, 15-16.
35. Chellappan, S.; Kiran Kumar Reddy, G. S.; Ali, A.; Nalam, M. N.; Anjum, S. G.; Cao, H.; Kairys, V.; Fernandes, M. X.; Altman, M. D.; Tidor, B.; Rana, T. M.; Schiffer, C. A.; Gilson, M. K. Design of Mutation-Resistant HIV Protease Inhibitors with the Substrate Envelope Hypothesis. Chem. Biol. Drug Des. 2007, 69, 298-313.
36. Bertsimas, D.; Tsitsiklis, J. N. Integer Programming Formulations. In Introduction to Linear Optimization; Athena Scientific: Belmont, MA, 1997; pp 451-478, 518.
37. Kingsford, C. L.; Chazelle, B.; Singh, M. Solving and Analyzing Side-Chain Positioning Problems Using Linear and Integer Programming. Bioinformatics 2005, 21, 1028-1036.
38. Althaus, E.; Kohlbacher, O.; Lenhof, H.-P.; Müller, P. A Combinatorial Approach to Protein Docking with Flexible Side-Chains. J. Comput. Biol. 2002, 4, 597-612.
39. Eriksson, O.; Zhou, Y.; Elofsson, A. Side Chain-Positioning as an Integer Programming Problem. In Lecture Notes in Computer Science; Vol. 2149. Proceedings of the 1st International Workshop on Algorithms in BioInformatics, BRICS, University of Aarhus, Denmark, 2001; Gascuel, O., Moret, B. M. E., Eds.; Springer-Verlag: New York, Secaucus, NJ, 2001; pp 129-141.
40. Klepeis, J. L.; Floudas, C. A.; Morikis, D.; Tsokos, C. G.; Argyropoulos, E.; Spruce, L.; Lambris, J. D. Integrated Computational and Experimental Approach for Lead Optimization and Design of Compstatin Variants with Improved Activity. J. Am. Chem. Soc. 2003, 125, 8422-8423.
41. Saraf, M. C.; Moore, G. L.; Goodey, N. M.; Cao, V. Y.; Benkovic, S. J.; Maranas, C. D. IPRO: An Iterative Computational Protein Library Redesign and Optimization Procedure. Biophys. J. 2006, 90, 4167-4180.
42. Markowitz, M.; Conant, M.; Hurley, A.; Schluger, R.; Duran, M.; Peterkin, J.; Chapman, S.; Patick, A.; Hendricks, A.; Yuen, G. J.; Hoskins, W.; Clendeninn, N.; Ho, D. D. A Preliminary Evaluation of Nelfinavir Mesylate, an Inhibitor of Human Immunodeficiency Virus (HIV)-1 Protease, to Treat HIV Infection. J. Infect. Dis. 1998, 177, 1533-1540.
43. Patrick, A. K.; Duran, M.; Cao, Y.; Shugarts, D.; Keller, M. R.; Mazabel, E.; Knowles, M.; Chapman, S.; Kuritzkes, D. R.; Markowitz, M. Genotypic and Phenotypic Characterization of Human Immuno-deficiency virus Type 1 Variants Isolated from Patients Treated with the Protease Inhibitor Nelfinavir. Antimicrob. Agents Chemother. 1998. 42, 2637-2644.
44. Scapin, G. Protein Kinase Inhibition: Different Approaches to Selective Inhibitor Design. Curr. Drug Targets 2006, 7, 1443-1454.
45. Fabian, M. A.; Biggs, W. H.; Treiber, D. K.; Atteridge, C. E.; Azimioara, M. D.; Benedetti, M. G.; Carter, T. A.; Ciceri, P.; Edeen, P. T.; Floyd, M.; Ford, J. M.; Galvin, M.; Gerlach, J. L.; Grotzfeld, R. M.; Herrgard, S.; Insko, D. E.; Insko, M. A.; Lai, A. G.; Lelias, J. M.; Mehta, S. A.; V., M. Z.; Velasco, A. M.; Wodicka, L. M.; Patel, H. K.; P., Z. P.; Lockhart, D. J. A Small Molecule-Kinase Interaction Map for Clinical Kinase Inhibitors. Nat. Biotechnol. 2005, 23, 329-336.
46. Ponder, J. W.; Richards, F. M. Tertiary Templates for Proteins. Use of Packing Criteria in the Enumeration of Allowed Sequences for Different Structural Classes. J. Mol. Biol. 1987, 193, 775-791.
47. Dunbrack, R. L.; Cohen, F. E. Bayesian Statistical Analysis of Protein Side-Chain Rotamer Preferences. Protein Sci. 1997, 6, 1661-1681.
48. Gordon, D. B.; Marshall, S. A.; Mayo, S. L. Energy Functions for Protein Design. Curr. Opin. Struct. Biol. 1999, 9, 509-513.
49. Desmet, J.; De Maeyer, M. D.; Hazes, B.; Lasters, I. The Dead-End Elimination Theorem and its use in Protein Side-Chain Positioning. Nature 1992, 356, 539-542.
50. Goldstein, R. F. Efficient Rotamer Elimination Applied to Protein Side-Chains and Related Spin Glasses. Biophys. J. 1994, 66, 1335-1340.
51. Sitkoff, K. A.; Sharp, K. A.; Honig, B. Accurate Calculation of Hydration Free Energies Using Macroscopic Solvent Models. J. Phys. Chem. 1994, 98, 1978-1988.
52. Brooks, B. R.; Bruccoleri, R. E.; Olafson, B. D.; States, D. J.; Swaminathan, S.; Karplus, M. CHARMM: A Program for Macromolecular Energy, Minimization, and Dynamics Calculations. J. Comput. Chem. 1983, 4, 187-217.
53. Lee, L.; Tidor, B. Optimization of Electrostatic Binding Free Energy. J. Chem. Phys. 1997, 106, 8681-8690.
54. Kangas, E.; Tidor, B. Optimizing Electrostatic Affinity in Ligand-Receptor Binding: Theory, Computation, and Ligand Properties. J. Chem. Phys. 1998, 109, 7522-7545.
55. Kangas, E.; Tidor, B. Electrostatic Specificity in Molecular Ligand Design. J. Chem. Phys. 2000, 112, 9120-9231.
56. Kangas, E.; Tidor, B. Electrostatic Complementarity at Ligand Binding Sites: Application to Chorismate Mutase. J. Phys. Chem. B 2001, 105, 880-888.
57. Gilson, M. K.; Sharp, K. A.; Honig, B. H. Calculating the Electrostatic Potential of Molecules in Solution: Method and Error Assessment. J. Comput Chem 1987, 9, 327-335.
58. Gilson, M. K.; Honig, B. Calculation of the Total Electrostatic Energy of a Macromolecular System: Solvation Energies, Binding Energies, and Conformational Analysis. Proteins 1988, 4, 7-18.
59. Sharp, K. A.; Honig, B. H. Electrostatic Interactions in Macromolecules: Theory and Applications. Annu. Rev. Biophys. Chem. 1990, 19, 301-332.
60. MATLAB, versions 6.0.0.88 (R12) and 7.1.0.183; The Mathworks, Inc.: Natick, MA, 2000/2005.
61. Cplex, version 9.0; ILOG, Inc.: Gentilly, France, 2003.
62. GAMS, version 2.5 (21.3); GAMS Development Corporation: Washington, DC, 2004.
63. Das, K.; Clark, A. D.; Lewi, P. J.; Heeres, J.; de Jonge, M. R.; Koymans, L. M. H.; Vinkers, H. M.; Daeyaert, F.; Ludovici, D. W.; Kukla, M. J.; De Corte, B.; Kavash, R. W.; Ho, C. Y.; Ye, H.; Lichtenstein, M. A.; Andries, K.; Pauwels, R.; de Bethune, M.-P.; Boyer, P. L.; Clark, P.; Hughes, S. H.; Janssen, P. A. J.; Arnold, E. Roles of Conformational and Positional Adaptability in Structure-Based Design of TMC125-R165335 (Etravirine) and Related Non-Nucleoside Reverse Transcriptase Inhibitors that are Highly Potent and Effective Against Wild-Type and Drug-Resistant HIV-1 Variants. J. Med. Chem. 2004, 47, 2550-2560.
64. Kangas, E.; Tidor, B. Charge Optimization Leads to Favorable Electrostatic Binding Free Energy. Phys. Rev. E 1999, 59, 5958-5961.
65. Maisnier-Patin, S.; Andersson, D. I. Adaptation to the Deleterious Effects of Antimicrobial Drug Resistance Mutations by Compensatory Evolution. Res. Microbiol. 2004, 155, 360-369.
66. Lee, L.-P.; Tidor, B. Optimization of Binding Electrostatics: Charge Complementarity in the Barnase-Barstar Protein Complex. Protein Sci. 2001, 10, 362-377.
67. Erickson-Vitanen, S.; Klabe, R. M.; Cawood, P. G.; O'Neal, P. L.; Meek, J. L. Potency and Selectivity of Inhibition of Human Immunodeficiency Virus Protease by a Small Nonpeptide Cyclic Urea, DMP 323. Antimicrob. Agents Chemother. 1994, 38, 1628-1634.
68. Cigler, P.; Kozisek, M.; Rezacova, P.; Brynda, J.; Otwinowski, Z.; Pokorna, J.; Plesek, J.; Gruner, B.; Doleckova-Maresova, L.; Masa, M.; Sedlacek, J.; Bodem, J.; Krausslich, H. G.; Kral, V.; Konvalinka, J. From Nonpeptide Toward Noncarbon Protease Inhibitors: Metallacarboranes as Specific and Potent Inhibitors of HIV Protease. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 15394-15399.
69. Havranek, J. J.; Harbury, P. B. Automated Design of Specificity in Molecular Recognition. Nat. Struct. Biol. 2003, 10, 45-52.
70. Bolon, D. N.; Grant, R. A.; Baker, T. A.; Sauer, R. T. Specificity Versus Stability in Computational Protein Design. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 12724-12729.
71. Green, D. F.; Dennis, A. T.; Fam, P. S.; Tidor, B.; Jasanoff, A. Rational Design of New Binding Specificity by Simultaneous Mutagenesis of Calmodulin and a Target Peptide. J. Biol. Chem. 2006, 45, 12547-12559.
72. Wartha, F.; Horn, A. H. C.; Meiselbach, H.; Sticht, H. Molecular Dynamics Simulations of HIV-1 Protease Suggest Different Mechanisms Contributing to Drug Resistance. J. Chem. Theor. Comput. 2005, 1, 315-324.
73. Ode, H.; Ota, M.; Neya, S.; Hata, M.; Sugiura, W.; Hoshino, T. Resistant Mechanism Against Nelfinavir of Human Immunodeficiency Virus Type 1 Proteases. J. Phys. Chem. B 2005, 109, 565-574.
74. Colonno, R.; Rose, R.; McLaren, C.; Thiry, A.; Parkin, N.; Friborg, J. Identification of I50L as the Signature Atazanavir (ATV)-Resistance Mutation in Treatment-Naive HIV-1-Infected Patients Receiving ATV-Containing Regimens. J. Infect. Dis. 2004, 189, 1802-1810.
75. Yanchunas, J., Jr; Langley, D. R.; Tao, L.; Rose, R. E.; Friborg, J.; Colonno, R. J.; Doyle, M. L. Molecular Basis for Increased Susceptibility of Isolates with Atazanavir Resistance-Conferring Substitution I50L to Other Protease Inhibitors, Antimicrob. Agents Chemother. 2005, 49, 3825-3832.
76. Ahn, J. S.; Radhakrishnan, M. L.; Mapelli, M.; Choi, S.; Tidor, B.; Cuny, G. D.; Musacchio, A.; Yeh, L. A.; Kosik, K. S. Defining Cdk5 Ligand Chemical Space with Small Molecule Inhibitors of Tau Phosphorylation. Chem. Biol. 2005, 12, 811-823.
77. Sims, P. A.; Wong, C. F.; McCammon, J. A. Charge Optimization of the Interface between Protein Kinases and their Ligands. J. Comput. Chem. 2004, 25, 1416-1429.
78. Davis, B.; Afshar, M.; Varani, G.; Murchie, A. I. H.; Karn, J.; Lentzen, G.; Drysdale, M.; Bower, J.; Potter, A. J.; Starkey, I. D.; Swarbrick, T.; Aboul-ela, F. Rational Design of Inhibitors of HIV-1 TAR RNA through the Stabilisation of Electrostatic "Hot Spots". J. Mol. Biol. 2004, 336, 343-356.
79. Tomic, S.; Bertosa, B.; Wang, T.; Wade, R. C. COMBINE Analysis of the Specificity of Binding of Ras Proteins to their Effectors. Proteins: Struct., Funct., Bioinformat. 2007, 67, 435-447.
80. Jain, T.; Jayaram, B. Computational Protocol for Predicting the Binding Affinities of Zinc Containing Metalloprotein-Ligand Complexes. Proteins: Struct., Funct., Bioinformat. 2007, 67, 1167-1178.
81. Johnson, S. R.; Yue, H.; Conder, M. L.; Shi, H.; Doweyko, A. M.; Lloyd, J.; Levesque, P. Estimation of hERG Inhibition of Drug Candidates using Multivariate Property and Pharmacophore SAR. Bioorg. Med. Chem. 2007, 15, 6182-6192.
82. Joughin, B. A.; Tidor, B.; Yaffe, M. B. A Computational Method for the Analysis and Prediction of Protein:Phosphopeptide-Binding Sites. Protein Sci. 2005, 14, 131-139.
83. Jones, S.; Shanahan, H. P.; Berman, H. M.; Thornton, J. M. Using Electrostatic Potentials to Predict DNA-Binding Sites on DNA-Binding Proteins. Nucleic Acids Res. 2003, 31, 7189-7198.
84. Nair, A. C.; Jayatilleke, P.; Wang, X.; Miertus, S.; Welsh, W. J. Computational Studies on Tetrahydropyrimidine-2-one HIV-1 Protease Inhibitors: Improving Three-Dimensional Quantitative Structure-Activity Relationship Comparative Molecular Field Analysis Models by Inclusion of Calculated Inhibitor- and Receptor-Based Properties. J. Med. Chem. 2002, 45, 973-983.
85. Sheinerman, F. B.; Giraud, E.; Laoui, A. High Affinity Targets of Protein Kinase Inhibitors Have Similar Residues at the Positions Energetically Important for Binding. J. Mol. Biol. 2005, 352, 1134-1156.
86. Armstrong, K. A.; Tidor, B.; Cheng, A. C. Optimal Charges in Lead Progression: A Structure-Based Neuraminidase Case Study. J. Med. Chem. 2006, 49, 2470-2477.
87. Fischer, W.; Perkins, S.; Theiler, J.; Bhattacharya, T.; Yusim, K.; Funkhouser, R.; Ruiken, C.; Haynes, B.; Letvin, N.; Walker, B.; Hahn, B.; Korber, B. Polyvalent Vaccines for Optimal Coverage of Potential T-CeIl Epitopes in Global HIV-1 Variants. Nat. Med. (N. Y.) 2007, 13, 100-106.
88. Vider-Shalit, T.; Raffaeli, S.; Louzoun, Y. Virus-epitope Vaccine Design: Informatic Matching the HLA-I Polymorphism to the Virus Genome. Mol. Immunol. 2007, 44, 1253-1261.
89. Munoz, N.; Bosch, F. X.; Castellsague, X.; Diaz, M.; de Sanjose, S.; Hammouda, D.; Shah, K. V.; Meijer, C. J. L. M. Against Which Human Papillomavirus Types Shall we Vaccinate and Screen? The International Perspective. Int. J. Cancer 2004, 111, 278-285.
90. Holley, L. H.; Goudsmit, J.; Karplus, M. Prediction of Optimal Peptide Mixtures to Induce Broadly Neutralizing Antibodies to Human Immunodeficiency Virus Type 1. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 6800-6804.